initiatives to Black, Indigenous, and people of color, and other medically underserved communities. (E) Assessment of the training, capacity, and ongoing technical assistance needed for providers to effectively implement such pregnancy intention screening protocols. (F) Assessment of whether referral systems for selected protocols follow evidence-based standards that ensure access to comprehensive culturally competent and gender affirming health services and appropriate follow-up care. (G) Measuring through rigorous methods the effect of such initiatives on key health outcomes. (2) Cost study The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall, by grant or contract, conduct a study assessing the time and cost for providers to administer pregnancy intention screening tools and provide related counseling in a diverse array of settings. (3) Consultation with independent experts In conducting any evaluation under paragraphs (1) and (2), the Director of the Centers for Disease Control and Prevention shall consult with physicians, physician assistants, advanced practice registered nurses, registered nurses, nurse midwives, behavioral health providers, other health care providers who specialize in reproductive and sexual health, human services providers, and other experts in public health, clinical practice, program evaluation, and research. (4) Report Not later than one year after the last day of the demonstration program under this section, the Director of the Centers for Disease Control and Prevention shall submit to Congress a report on the results of the evaluation and study conducted under paragraphs (1) and (2) and shall make the report publicly available. (f) Funding (1) Authorization of appropriations To carry out this section, there is authorized to be appropriated $10,000,000 for each of fiscal years 2024 through 2026. (2) Limitation Not more than 20 percent of funds appropriated to carry out this section pursuant to paragraph (1) for a fiscal year may be used